Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Trial details
- Registry ID
- NCT01953926
- Phase
- Phase 2
The FDA approved Fulvestrant (Faslodex) on 25 Apr 2002.
Drug identity checked against registry records
Also recorded as Faslodex
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2002-04-25Day | Fulvestrant | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA021344", "applicant_as_listed_by_fda": "ASTRAZENECA", "brand_names": ["FASLODEX"], "active_ingredients": ["FULVESTRANT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20020425", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |